1. HOME
2. Research Insight
3. F. Hoffmann-La Roche Ltd. (Switzerland) and Hologic, Inc. (US) are Leading Players in the CT/NG Testing Market

The global CT/NG testing market is projected to reach USD 2.7 billion by 2028 from USD 1.7 billion in 2023, at a CAGR of 8.6% during the forecast period. Factors such as the increasing prevalence of CT/NG infections, increasing investments and funds in CT/NG and growing awareness for diseases diagnosis are driving the growth of this market. However, operational barriers and the high cost of CT/NG testing instruments is likely to hamper the growth of CT/NG testing market.

The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN (Netherlands), PerkinElmer Inc. (US), Bio-Rad Laboratories, Inc. (US), Siemens Healthineers AG (Germany), Danaher (US), Becton, Dickinson and Company (US), Seegene, Inc. (South Korea), Meridian Bioscience Inc. (US), Binx Health, Inc. (US), Visby Medical, Inc. (US), Geneproof A.S. (Czech Republic), Bioneer Corporation (South Korea), Genetic Signatures (Australia), Microbiologics, Inc. (US), Vircell S.L. (Spain), Sansure Biotech Inc. (China), ELITechGroup (France), Molbio Diagnostics Pvt. Ltd. (India), Operon S.A. (Spain), Tianlong Technology Co., Ltd.  (China), and Goffin Molecular Technologies B.V. (Netherlands).

To know about the assumptions considered for the study download the pdf brochure

F. Hoffmann-La Roche Ltd. (Switzerland) maintained its dominant position in the CT/NG testing market in 2022. The company's strong distribution networks in North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa have contributed to its maintained leadership in the market. Roche continues to be at the top from a robust direct and indirect distribution network worldwide, which helps mitigate the impact of demand fluctuations across different regions. To further enhance its market dominance, the company employs inorganic growth strategies, such as partnerships and acquisitions. In September 2021, the company announced the acquisition of TIB Molbiol (Germany) to expand its PCR test portfolio with a wide range of assays for infectious diseases. In 2020, Roche collaborated with Illumina Inc. (US) to expand the utilization of NGS-based testing in the field of oncology. These strategic initiatives enable Roche to secure a larger market share and strengthen its position in the CT/NG testing market.

In 2022, Hologic, Inc. (US) held a significant market share in the CT/NG testing market. The company's leading position can be attributed to its robust global sales and distribution network, which effectively promotes its products across various countries. Hologic has strategically emphasized R&D initiatives to develop innovative and superior offerings compared to its competitors. By investing in R&D, the company aims to optimize its product portfolio and allocate capital wisely, thereby fostering future growth and maintaining its competitiveness in the diagnostics segment.

Furthermore, Hologic implements both organic and inorganic strategies, such as product launches and acquisitions, to further strengthen its standing in the CT/NG testing market. In June 2021, the company made a significant acquisition of Mobidiag Oy (Finland), a renowned innovator in molecular diagnostic testing. This strategic move expanded Hologic's product line considerably and enhanced its market visibility, bolstering its overall position in the industry.

Abbott Laboratories, a prominent player in the global CT/NG testing market, secured a significant market share in the CT/NG testing market in 2022. The company's strong presence in the US serves as a foundation for expanding its operations in emerging markets, thereby strengthening its geographical reach. By continuously developing new products, Abbott caters to a diverse customer base across various geographic locations. To ensure continued access to its products, the company places a strong emphasis on optimizing its global supply chain. This strategic focus further reinforces the company's ability to retain its leading position in the CT/NG testing market. In addition to its R&D efforts and supply chain management, Abbott leverages organic growth strategies such as product launches to maintain its market leadership. For example, in March 2021, the company received Emergency Use Authorization (EUA) from the FDA for its laboratory PCR assay, Alinity m Resp-4-Plex molecular assay. This assay detected and differentiated SARS-COV-2, flu A, flu B, and RSV in a single test. Such product launches contribute to Abbott's continued success and its sustained leading position in the CT/NG testing market.

Related Reports:

CT/NG Testing Market by Product (Assays, Kits & Analyzers), Test Type (Laboratory, Point-of-care Testing), Technology (INAAT, PCR, Immunodiagnostics), End User (Diagnostic Labs, Hospitals & Clinics) & Region - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]